WTR Healthcare Happenings

Biotech M&A Is Back: What's Driving the 2026 Deal Surge

Joe Brunetto

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 11:05

In this episode of WTR Healthcare Happenings, host Tim Gerdeman is joined by healthcare equity research analyst Robert Sassoon to discuss the rebound in biotech and pharma M&A. Robert explains why 2026 is shaping up as the strongest M&A environment since 2019, with 35 disclosed-value deals totaling roughly $97 billion in just over six months.  The discussion covers rising deal sizes, the patent cliff, a more permissive antitrust backdrop, improved drug-pricing clarity, pharma’s estimated $2.1 trillion in acquisition capacity, and better financing conditions. Tim and Robert also examine the types of clinical-stage assets attracting buyers, key therapeutic areas including oncology, immunology, metabolic disease, CNS, and the growing role of China and AI-driven drug discovery in the next wave of transactions.